8/103 sources · 3 publishersUpdated Oct 22, 13:06 UTC
Sartorius Stedim Biotech posts 9‑month sales of €2.29 bn and maintains 2026 guidance
Sartorius Stedim Biotech reported 9‑month 2026 sales of €2.289 bn, a 6.5% rise in constant currencies, with EBITDA of €716 mn and a margin of 31.3%. Net profit grew 26.7% to €277 mn and non‑GAAP EPS was €2.84. The company confirmed its full‑year outlook, expecting 6‑10% sales growth and an EBITDA margin slightly above 31% for the year.
Why it matters
The company’s strong profit margin and unchanged guidance suggest continued earnings growth for the fiscal year, supporting the current valuation assumptions of investors.
Key facts
- 19‑month sales revenue was €2,289 million, up 6.5% in constant currencies (reported 4.3%). finanznachrichten.de
- 2Underlying EBITDA was €716 million, a 4.8% increase, giving a margin of 31.3%. finanznachrichten.de
- 3Net profit amounted to €277 million, up 26.7% year‑on‑year. finanznachrichten.de
- 4Non‑GAAP earnings per share were €2.84. seekingalpha.com
- 5Management reaffirmed 2026 guidance, targeting 6‑10% sales growth and an EBITDA margin slightly above 31%. finanznachrichten.de
- 6Free cash flow rose to €264 million. tradingview.com
Summary written by AlphAI AI Desk from 3 of 3 sources. Not investment advice. Figures are as stated by the linked sources.